Covidien Announces FDA 510(k) Clearance of the Nellcor™ Bedside SpO2 Patient Monitoring System
08:00 EDT 30 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Covidien
(NYSE: COV), a leading global provider of healthcare products and
recognized innovator in patient monitoring and respiratory care
solutions, today announced the U.S. Food and Drug Administration (FDA)
has granted...
Other Sources for this Article
Covidien
Rhonda Luniak, 303-305-2263
Vice President
R&MS
Communications
rhonda.luniak@covidien.com
or
Bruce
Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Coleman
Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd
Carpenter, 508-452-4363
Director
Investor Relations
todd.carpenter@covidien.com
More From BioPortfolio on "Covidien Announces FDA 510(k) Clearance of the Nellcor™ Bedside SpO2 Patient Monitoring System"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
